157 related articles for article (PubMed ID: 37443286)
1. Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target.
Malkomes P; Lunger I; Oppermann E; Lorenz J; Faqar-Uz-Zaman SF; Han J; Bothur S; Ziegler P; Bankov K; Wild P; Bechstein WO; Rieger MA
Cancer Gene Ther; 2023 Oct; 30(10):1346-1354. PubMed ID: 37443286
[TBL] [Abstract][Full Text] [Related]
2. Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53.
Malkomes P; Lunger I; Oppermann E; Abou-El-Ardat K; Oellerich T; Günther S; Canbulat C; Bothur S; Schnütgen F; Yu W; Wingert S; Haetscher N; Catapano C; Dietz MS; Heilemann M; Kvasnicka HM; Holzer K; Serve H; Bechstein WO; Rieger MA
Oncogene; 2021 Jun; 40(25):4352-4367. PubMed ID: 34103685
[TBL] [Abstract][Full Text] [Related]
3. TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer.
Miyoshi N; Ishii H; Mimori K; Tanaka F; Hitora T; Tei M; Sekimoto M; Doki Y; Mori M
Ann Surg Oncol; 2010 Apr; 17(4):967-72. PubMed ID: 20033322
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA‑214 suppresses the viability, migration and invasion of human colorectal carcinoma cells via targeting transglutaminase 2.
Shan H; Zhou X; Chen C
Mol Med Rep; 2019 Aug; 20(2):1459-1467. PubMed ID: 31173203
[TBL] [Abstract][Full Text] [Related]
5. TGM2 interference regulates the angiogenesis and apoptosis of colorectal cancer via Wnt/β-catenin pathway.
Yang P; Yu D; Zhou J; Zhuang S; Jiang T
Cell Cycle; 2019 May; 18(10):1122-1134. PubMed ID: 31010374
[TBL] [Abstract][Full Text] [Related]
6. MiR-532-3p suppresses colorectal cancer progression by disrupting the ETS1/TGM2 axis-mediated Wnt/β-catenin signaling.
Gu C; Cai J; Xu Z; Zhou S; Ye L; Yan Q; Zhang Y; Fang Y; Liu Y; Tu C; Wang X; He J; Li Q; Han L; Lin X; Li A; Liu S
Cell Death Dis; 2019 Sep; 10(10):739. PubMed ID: 31570702
[TBL] [Abstract][Full Text] [Related]
7. TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells.
Fu J; Yang QY; Sai K; Chen FR; Pang JC; Ng HK; Kwan AL; Chen ZP
Neuro Oncol; 2013 Oct; 15(10):1353-65. PubMed ID: 23877317
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic cancer.
Zhang S; Yao HF; Li H; Su T; Jiang SH; Wang H; Zhang ZG; Dong FY; Yang Q; Yang XM
Cell Oncol (Dordr); 2023 Oct; 46(5):1473-1492. PubMed ID: 37246171
[TBL] [Abstract][Full Text] [Related]
9. Kaempferol induces ROS-dependent apoptosis in pancreatic cancer cells via TGM2-mediated Akt/mTOR signaling.
Wang F; Wang L; Qu C; Chen L; Geng Y; Cheng C; Yu S; Wang D; Yang L; Meng Z; Chen Z
BMC Cancer; 2021 Apr; 21(1):396. PubMed ID: 33845796
[TBL] [Abstract][Full Text] [Related]
10. Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells.
Li X; Ma Y; Wu J; Ni M; Chen A; Zhou Y; Dai W; Chen Z; Jiang R; Ling Y; Yao Q; Chen W
Drug Resist Updat; 2023 Mar; 67():100930. PubMed ID: 36736043
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminase 2 Regulates Self-renewal and Stem Cell Marker of Human Colorectal Cancer Stem Cells.
Kang S; Oh SC; Min BW; Lee DH
Anticancer Res; 2018 Feb; 38(2):787-794. PubMed ID: 29374703
[TBL] [Abstract][Full Text] [Related]
12. Amplification of transglutaminase 2 enhances tumor-promoting inflammation in gastric cancers.
Cho SY; Oh Y; Jeong EM; Park S; Lee D; Wang X; Zeng Q; Qin H; Hu F; Gong H; Liu X; Zhang G; Na D; Lee J; Chae J; Suh YS; Kong SH; Lee HJ; Kim JI; Park H; Zhang C; Yang HK; Lee C
Exp Mol Med; 2020 May; 52(5):854-864. PubMed ID: 32467608
[TBL] [Abstract][Full Text] [Related]
13. TGM2: a cell surface marker in esophageal adenocarcinomas.
Leicht DT; Kausar T; Wang Z; Ferrer-Torres D; Wang TD; Thomas DG; Lin J; Chang AC; Lin L; Beer DG
J Thorac Oncol; 2014 Jun; 9(6):872-81. PubMed ID: 24828664
[TBL] [Abstract][Full Text] [Related]
14. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer.
Park KS; Kim HK; Lee JH; Choi YB; Park SY; Yang SH; Kim SY; Hong KM
J Cancer Res Clin Oncol; 2010 Apr; 136(4):493-502. PubMed ID: 19763620
[TBL] [Abstract][Full Text] [Related]
15. Genomic variants reveal differential evolutionary constraints on human transglutaminases and point towards unrecognized significance of transglutaminase 2.
Thangaraju K; Király R; Demény MA; András Mótyán J; Fuxreiter M; Fésüs L
PLoS One; 2017; 12(3):e0172189. PubMed ID: 28248968
[TBL] [Abstract][Full Text] [Related]
16. Novel peptide GX1 inhibits angiogenesis by specifically binding to transglutaminase-2 in the tumorous endothelial cells of gastric cancer.
Lei Z; Chai N; Tian M; Zhang Y; Wang G; Liu J; Tian Z; Yi X; Chen D; Li X; Yu P; Hu H; Xu B; Jian C; Bian Z; Guo H; Wang J; Peng S; Nie Y; Huang N; Hu S; Wu K
Cell Death Dis; 2018 May; 9(6):579. PubMed ID: 29785022
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of transglutaminase 2 reduces efferocytosis in human macrophages: Role of CD14 and SR-AI receptors.
Eligini S; Fiorelli S; Tremoli E; Colli S
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):922-30. PubMed ID: 27378395
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation.
Yeo SY; Itahana Y; Guo AK; Han R; Iwamoto K; Nguyen HT; Bao Y; Kleiber K; Wu YJ; Bay BH; Voorhoeve M; Itahana K
Elife; 2016 Mar; 5():e07101. PubMed ID: 26956429
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 2 is upregulated in primary hepatocellular carcinoma with early recurrence as determined by proteomic profiles.
Yamaguchi H; Kuroda K; Sugitani M; Takayama T; Hasegawa K; Esumi M
Int J Oncol; 2017 May; 50(5):1749-1759. PubMed ID: 28339069
[TBL] [Abstract][Full Text] [Related]
20. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
Ai L; Kim WJ; Demircan B; Dyer LM; Bray KJ; Skehan RR; Massoll NA; Brown KD
Carcinogenesis; 2008 Mar; 29(3):510-8. PubMed ID: 18174247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
